Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2795)	11/6/2012 7:07:19 PM
From: DewDiligence_on_SI	Respond to of 3202

Broad second-line label is what PFE was hoping for.

To: scaram(o)uche who wrote (2795)	11/7/2012 12:57:58 PM
From: Biotech Jim	Read Replies (1) \| Respond to of 3202

The label for XELJANZ (tofacitinib) is bullish for the INCY compound baricitinib (INCB28050) and functionally/structurally related congeners in terms of intended target patient population and its use in second line for RA and not requiring a prior biologic treatment. labeling.pfizer.com I note this passage in terms of the modest burden of LFTs for 5 mg BID XELJANZ (the only dose approved) : "Routine monitoring of liver tests and prompt investigation of the causes of liver enzyme elevations is recommended to identify potential cases of drug-induced liver injury. If drug-induced liver injury is suspected, the administration of XELJANZ should be interrupted until this diagnosis has been excluded." The MSDS for tofacitinib is of interest. pfizer.com